These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 26318692

  • 1. Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review.
    da Silva LS, de Campos KV, de Melo AK, de Brito DC, Braz AS, Freire EA.
    Rev Bras Reumatol; 2015; 55(6):531-5. PubMed ID: 26318692
    [Abstract] [Full Text] [Related]

  • 2. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
    Clain JM, Specks U.
    Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L, Specks U, Sethi S, Fervenza FC.
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [Abstract] [Full Text] [Related]

  • 4. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
    Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L, French Vasculitis Study Group.
    Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of ANCA-associated vascularitides].
    Guillevin L, Pagnoux C.
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [Abstract] [Full Text] [Related]

  • 6. Biologics for ANCA-associated vasculitis.
    Murgia G, Firinu D, Manconi PE, Del Giacco SR.
    Inflamm Allergy Drug Targets; 2014 May; 13(4):275-87. PubMed ID: 24998311
    [Abstract] [Full Text] [Related]

  • 7. [ANCA-associated vasculitis].
    Holle JU.
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [Abstract] [Full Text] [Related]

  • 8. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR, European Vasculitis Society (EUVAS).
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [Abstract] [Full Text] [Related]

  • 9. S3. Rituximab for ANCA-associated vasculitides: the French experience.
    Charles P, Guillevin L.
    Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
    [No Abstract] [Full Text] [Related]

  • 10. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM, D'Cruz DP.
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [Abstract] [Full Text] [Related]

  • 11. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group.
    N Engl J Med; 2014 Nov 06; 371(19):1771-80. PubMed ID: 25372085
    [Abstract] [Full Text] [Related]

  • 12. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group.
    N Engl J Med; 2010 Jul 15; 363(3):211-20. PubMed ID: 20647198
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Advances in therapy for ANCA-associated vasculitis.
    Geetha D, Seo P.
    Curr Rheumatol Rep; 2012 Dec 15; 14(6):509-15. PubMed ID: 22895899
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KG, Jayne DR.
    Rheumatology (Oxford); 2015 Jul 15; 54(7):1153-60. PubMed ID: 25477054
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC, Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.
    J Am Soc Nephrol; 2015 Apr 15; 26(4):976-85. PubMed ID: 25381429
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
    Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP.
    J Rheumatol; 2012 Nov 15; 39(11):2153-6. PubMed ID: 22984269
    [Abstract] [Full Text] [Related]

  • 20. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.
    van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmattulla C.
    Ann Rheum Dis; 2017 Jun 15; 76(6):1064-1069. PubMed ID: 27899372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.